ArticleActa neuropathologica communications2018
A common antigenic motif recognized by naturally occurring human V
Abstract read
In one paragraph
Article in Acta neuropathologica communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cryo-EM structures of ALECT2 filaments from human renal biopsies.Nature communications · 2026Article
- Large-scale seroepidemiology uncovers nephro-urological pathologies in people with tau autoimmunity.PLoS biology · 2025Article
- Insights into the Structural Conformations of the Tau Protein in Different Aggregation Status.Molecules (Basel, Switzerland) · 2023Review
- Human Polymerase δ-Interacting Protein 2 (PolDIP2) Inhibits the Formation of Human Tau Oligomers and Fibrils.International journal of molecular sciences · 2021Article
- Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation.Acta neuropathologica communications · 2020Article
- A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms.Frontiers in molecular biosciences · 2020Article
- Intersection of pathological tau and microglia at the synapse.Acta neuropathologica communications · 2019Review
- Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.Acta neuropathologica · 2019Article
- Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated SerActa neuropathologica communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Adrian ApetriJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands. AApetri@its.jnj.com.
Rosa CrespoJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Jarek JuraszekJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Gabriel PascualJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Roosmarijn JansonJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Xueyong ZhuDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Heng ZhangDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Elissa KeoghJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Trevin HollandJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Jay WadiaJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Hanneke VerveenJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Berdien SiregarJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Michael MrosekProteros Biostructures GmbH, Bunsenstraße 7a, 82152, Planegg, Germany.
Renske TaggenbrockJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Jeroenvan AmeijdeJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Hanna InganäsJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Margot van WinsenJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Martin H KoldijkJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
David ZuijdgeestJanssen Vaccines and Prevention, Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 6, Leiden, CN, 2333, the Netherlands.
Marianne BorgersJanssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
Koen DockxMolecular and Cellular Pharmacology, Discovery Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
Esther J M StoopJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Wenli YuDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Els C Brinkman-van der LindenJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Kimberley UmmenthumDepartment of Pathology, Amsterdam Neuroscience, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands.
Kristof van KolenJanssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
Marc MerckenJanssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
Stefan SteinbacherProteros Biostructures GmbH, Bunsenstraße 7a, 82152, Planegg, Germany.
Donata de MarcoJanssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
Jeroen J HoozemansDepartment of Pathology, Amsterdam Neuroscience, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Wouter KoudstaalJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Jaap GoudsmitJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
Funding
Medical Research Council G0400074
Abstract
Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer's Disease (AD). By interrogating IgG
Indexed as
AdolescentAdultAgedAntibody SpecificityB-LymphocytesCrystallizationDose-Response Relationship, DrugFemaleHumansImmunodominant EpitopesImmunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsMaleMicrogliaMicroscopy, Atomic ForceImmunodominant EpitopesImmunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsProtein Aggregatestau ProteinsAlzheimer’s diseaseAntigenic motifMonoclonal antibodyTau protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.